We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

95 hedge funds and large institutions have $1.92B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,848% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $557K

76% more capital invested

Capital invested by funds: $1.09B → $1.92B (+$825M)

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

54% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 28

7% more funds holding

Funds holding: 89 → 95 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
95
Holders Change
+6
Holders Change %
+6.74%
% of All Funds
3.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
43
Reduced
28
Closed
10
Calls
$10.8M
Puts
$557K
Net Calls
+$10.3M
Net Calls Change
+$10.9M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$51.7M
2
CWAM
Columbia Wanger Asset Management
Illinois
+$36.4M
3
BB
BB Biotech
Switzerland
+$32.5M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$23.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
TI
Turner Investments
Pennsylvania
-$8.81M
2
BA
BlackRock Advisors
Delaware
-$8.25M
3
Wells Fargo
Wells Fargo
California
-$8.16M
4
DCM
Driehaus Capital Management
Illinois
-$6.07M
5
Millennium Management
Millennium Management
New York
-$5.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$6.52M +$1.71M +34,788 +51%
PAMU
27
Pictet Asset Management (UK)
United Kingdom
$6.48M -$2.59M -52,700 -34%
ACH
28
ArrowMark Colorado Holdings
Colorado
$6.42M +$4.23M +85,850 +554%
EMFAT
29
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.24M +$982K +19,940 +25%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$5.58M +$1.8M +36,605 +71%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$4.96M +$391K +7,951 +11%
TCIM
32
TIAA CREF Investment Management
New York
$4.8M +$26.4K +537 +0.7%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$4.03M +$867K +17,608 +38%
UBS AM
34
UBS AM
Illinois
$4M +$340K +6,900 +12%
AQR Capital Management
35
AQR Capital Management
Connecticut
$3.28M +$2.01M +40,800 +371%
DM
36
Deerfield Management
New York
$3.17M +$2.46M +50,000 New
BIM
37
BlackRock Investment Management
Delaware
$3.06M +$165K +3,357 +7%
Charles Schwab
38
Charles Schwab
California
$2.96M +$414K +8,409 +23%
Wells Fargo
39
Wells Fargo
California
$2.78M -$8.16M -165,838 -79%
Deutsche Bank
40
Deutsche Bank
Germany
$2.7M +$948K +19,250 +82%
Macquarie Group
41
Macquarie Group
Australia
$2.46M +$435K +8,829 +29%
BG
42
BlackRock Group
United Kingdom
$2.29M -$1.29M -26,300 -42%
Fidelity International
43
Fidelity International
Bermuda
$1.98M -$847K -17,200 -36%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.94M +$39.4K +800 +3%
DCM
45
Driehaus Capital Management
Illinois
$1.59M -$6.07M -123,351 -83%
AC
46
Ascend Capital
California
$1.57M -$14.7K -298 -1%
TA
47
Teachers Advisors
New York
$1.49M +$52.6K +1,069 +5%
Invesco
48
Invesco
Georgia
$1.43M +$1.11M +22,509 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$1.3M -$1.82M -37,000 -64%
ProShare Advisors
50
ProShare Advisors
Maryland
$1.29M +$390K +7,919 +63%
1
2
3 4 5

GEVA Hedge Fund Activity: Q3 2013 in Review

95 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q3 2013, worth a combined $1.92B — up 76% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new GEVA positions and 10 closed out — a net gain of 7 holders — while 43 added to existing stakes and 28 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $51.7M. The largest seller was Turner Investments, exiting entirely with an estimated $8.81M sold.

  • 95 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q3 2013, up from 89 in Q2 2013.
  • Funds reported $1.92B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q3 2013, up 76% quarter-over-quarter.
  • 17 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q3 2013 and 10 closed out, a net change of +7 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q3 2013 was Baker Bros. Advisors, an estimated $51.7M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q3 2013 was Turner Investments, an estimated $8.81M sold.

Based on aggregated 13F filings for Q3 2013.